left-arrow right-arrow pinterest facebook google_plus linkedin

ECOG-ACRIN EA1131

Status:

Recruiting | Phase III

Official Title:

Testing Platinum-Based Chemotherapy After Surgery In Triple-Negative Breast Cancers

Study Purpose:

To determine if getting more treatment with capecitabine to any good and bad effects of getting more treatment with cisplatin or carboplatin after surgery. The results of this study will provide knowledge as to what approach is better, the same or worse than using capecitabine chemotherapy.

Interventions:

  • Before study initiation, a central laboratory will test a sample of your tissue from a prior surgery to find out if your breast cancer is basal-like triple negative. This is a biomarker test  called PAM50,
  • Group 1: Observation (NO LONGER ADDING PATIENTS)
  • Group 2: Platinum-based chemotherapy(study group)
  • Quality of Life questionnaires and a blood collection
  • After the completion of study therapy, follow ups will consist of 10 years

Key Participation Requirements:

Gender:

Male and Female

Age:

19 years and older

Diagnosis:

Triple-Negative Breast Cancer

Eligibility:

Clinical stage II or III triple-negative breast cancer

ER PR negative

Her2 negative

No metastatic disease

Mastectomy, lumpectomy, or partial mastectomy acceptable

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

ECOG-ACRIN EA1131

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!